Dr. Ruoxi Hong: Precision Medical Oncology, Endocrine Resistance & Clinical Trials for Breast Cancer at Sun Yat-sen University Cancer Center

Professional Profile

Dr. Ruoxi Hong is an esteemed medical oncologist, Chief Physician, and Doctoral Supervisor in the Department of Medical Oncology at Sun Yat-sen University Cancer Center (SYSUCC). Recognized as a leading force in clinical and translational breast oncology, Dr. Hong focuses on solving complex drug resistance mechanisms in advanced breast cancer, pioneering personalized therapeutic algorithms, and driving high-impact clinical trials for breakthrough anti-cancer agents.

At SYSUCC, Dr. Hong plays an instrumental role in bridging laboratory discoveries with bedside patient care. Her clinical practice integrates multi-omic molecular diagnostics, next-generation sequencing (NGS), and liquid biopsies to guide line-by-line systemic therapy. She is especially renowned for her empathetic and meticulous management of young women facing breast cancer, offering integrated hereditary cancer genetic counseling, fertility protection, and tailored endocrine therapies.

Key Clinical Specializations

• Overcoming Endocrine Resistance in Advanced Breast Cancer: Formulating individualized subsequent-line regimens for HR-positive, HER2-negative metastatic breast cancer progressing on CDK4/6 inhibitors, incorporating novel selective estrogen receptor degraders (SERDs), PROTACs, PI3K/AKT/mTOR inhibitors, and innovative combinations.
• Precision Targeted & Antibody-Drug Conjugate (ADC) Therapies: Tailoring systemic regimens using next-generation ADCs (anti-HER2, anti-Trop2, anti-HER3) for HER2-low, HER2-positive, and triple-negative breast cancer (TNBC), managing therapeutic sequencing to maximize survival benefits while proactively mitigating adverse events.
• Breast Cancer Immunotherapy & Microenvironment Remodeling: Exploring biomarker-selected immune checkpoint blockade strategies in immunologically complex subtypes, converting "cold" non-responsive tumors into inflamed, therapy-sensitive lesions.
• Young Breast Cancer & Hereditary Genetic Counseling: Comprehensive risk evaluation and customized clinical pathways for young patients, focusing on germline BRCA1/2 genetic testing, PARP inhibitor access, fertility preservation, and long-term ovarian function suppression.
• Core Investigator for Innovative Oncology Clinical Trials: Serving as Principal or Sub-Investigator for dozens of national and global Phase I–III clinical studies, providing eligible refractory patients with access to state-of-the-art investigational therapies.

Academic Leadership & Landmark Research (2024–2025)

Dr. Ruoxi Hong has established an extraordinary academic track record as corresponding author in premier international medical journals, reflecting her deep contributions to breast oncology science:

• Landmark Authorship in Journal of Clinical Oncology (JCO): Publishing landmark clinical cohort investigations and biomarker analyses evaluating novel combinatorial targeted strategies for advanced breast cancer patients, shaping global clinical practice.
• Mechanistic Breakthroughs in Molecular Cancer: Uncovering pivotal epigenetic and signaling pathway drivers underlying acquired resistance to endocrine-targeted regimens, identifying actionable targets to reverse therapeutic escape.
• Translational Insights in Signal Transduction and Targeted Therapy (STTT): Demonstrating how tumor microenvironment metabolic reprogramming governs response to immunotherapeutic interventions in refractory breast cancer subtypes.

International Patient Coordination & Fast-Track Access

China Medical Concierge – Shanghai (CMCS) provides dedicated health management and medical concierge services connecting domestic and overseas patients with top-tier oncologists. For patients seeking medical consultation with Dr. Ruoxi Hong at SYSUCC, CMCS delivers end-to-end support:

• Remote multidisciplinary review of pathology slides, immunohistochemistry (IHC), and genomic sequencing reports;
• Fast-track outpatient clinic scheduling at both Yuexiu and Huangpu campuses;
• Prescreening and clinical assessment for access to innovative Phase I–III drug clinical trials and early-access pipeline treatments;
• Full-journey medical translation, bilingual patient companionship, and longitudinal treatment monitoring.